Lupin’s US subsidiary, Lupin Pharmaceuticals has launched its niacin extended-release tablets USP, 500 mg, 750 mg, 1000 mg strengths having received final approval from the United States Food and Drug Administration (US FDA).
Lupin’s niacin extended-release tablets USP, 500 mg, 750 mg, 1000 mg strengths are the AB-rated generic equivalent of AbbVie’s Niaspan tablets 500 mg, 750 mg, 1000 mg and used with diet to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia.
Nilesh Gupta, Managing Director, Lupin said, “We are happy to launch this product having received approval from the US FDA. The launch bears testimony to our commitment to serving our customers and patients by bringing high quality, affordable medicines to the market.”
EP News Bureau – Mumbai
- Advertisement -
